Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma

Chemistry Central Journal

Muzaffar Iqbal¹  Tanveer A Wani¹  Nasr Y Khalil¹  Ibrahim A Darwish¹ 

[1] Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, 11451, Riyadh, Saudi Arabia

关键词: High throughput analysis;    Pharmacokinetic and toxicokinetic;    Tandem mass spectrometry;    Ultra performance liquid chromatography;    Lenalidomide;   

Others  :  787985
DOI  :  10.1186/1752-153X-7-7

 received in 2012-11-21, accepted in 2013-01-10,  发布年份 2013

【 摘 要 】

Background

Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. Validated sensitive method with high throughput is required for the determination of lenalidomide for pharmacokinetics and toxicokinetic studies. Ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is a preeminent analytical tool for rapid biomedical analysis.

Results

A simple, highly sensitive UPLC-MS/MS method was developed and validated for the determination of LND in rabbit and human plasma. After a simple protein precipitation using methanol, LND and carbamazepine (IS) were separated on Acquity UPLC BEH™ C₁₈ column (50 × 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisted of acetonitrile:water:formic acid (65:35:0.1%, v/v/v) pumped at a flow rate of 0.2 mL/min. LND and IS were eluted at 0.71 and 1.92 min, respectively. The mass spectrometric determination was carried out using an electrospray interface operated in the positive mode with multiple reaction monitoring (MRM) mode. The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively. The method was linear in the concentration range of 0.23–1000 ng/mL with a limit of quantitation of 0.23 ng/mL. All the validation parameters were in the ranges acceptable by the guidelines of analytical method validation.

Conclusion

The proposed UPLC-MS/MS method is simple, rapid and highly sensitive, and hence it could be reliable for pharmacokinetic and toxicokinetic study in both animals and humans.

【 授权许可】

   
2013 Iqbal et al; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kastritis E, Dimopoulos MA: The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 2007, 8:497-509.
• [2]Mitsiades CS, Mitsiades N: CC-5013 (Celgene). Curr Opin Investig Drugs 2004, 5:635-647.
• [3]Tariman JD: Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Clin J Oncol Nursing 2007, 11:569-574.
• [4]Sonneveld P, Palumbo A: Lenalidomide: a new therapy for multiple myeloma. EJHPP 2008, 14:58-61.
• [5]Shah SR, Tran TM: Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs 2007, 67:1869-1881.
• [6]Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A: Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 2008, 8:865-874.
• [7]Hideshima T, Richardson PG, Anderson KC: Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Invest Drugs 2006, 15:171-179.
• [8]Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
• [9]Anderson KC: Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Seminars Hematol 2005, 42:S3-S8.
• [10]Richardson P, Anderson K: Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004, 22:3212-3214.
• [11]Verhelle D, Corral LG, Wong K, Mueller JH, Parseval LM, Pergakes KJ, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KWH: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
• [12]Revlimid (lenalidomide) [Full Prescribing Information]. Summit, NJ: Celgene Corporation; 2012. [http://www.revlimid.com/pdf/REVLIMID_PI.pdf webcite]
• [13]Richardson PG, Schlossman RL, Weller E: Immunomodulatory drug CC 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
• [14]Sastry BS, Gananadhamu S, Prasad SVS, Venu GRK: New spectrophotometric methods for estimation of lenalidomide in pharmaceutical formulations. Int J PharmTech Res 2009, 1:416-419.
• [15]Darwish IA, Khalil NY, Bakheit AH, Alzoman NZ: A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine. Chem Cent J 2012, 6(1):118. BioMed Central Full Text
• [16]Saravanan G, Rao BM, Ravikumar M, Suryanarayana MV, Someswararao N, Acharyulu PVR: Development of an HPLC assay method for lenalidomide. Chromatographia 2007, 66:287-290.
• [17]Maheswara RL, Janardhan RK, Bhaskar RL, Raveendra Reddy P: Development of a rapid and sensitive HPLC assay method for lenalidomide capsules and its related substances. E-J Chem 2012, 9:1165-1174.
• [18]Tohnya TM, Hwang K, Lepper ER: Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 811:135-141.
• [19]Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA: Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit 2008, 5:620-627.
• [20]US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for Industry on Bioanalytical Method Validation. Rockville, MD: Department of Health and Human Services; 2001.
• [21]European Medicines Agency: guideline on bioanalytical method validation. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf webcite]